Literature DB >> 3902870

Effects of hypopituitarism and growth hormone replacement therapy on the production and utilization of glucose in childhood.

P F Bougneres, E Artavia-Loria, P Ferre, J L Chaussain, J C Job.   

Abstract

Glucose metabolism during fasting was investigated in 10 children aged 1.5 month-11.5 yr with deficiency of GH with or without other pituitary hormone deficiencies. After 10-16 h of fasting, mean plasma glucose was 56 +/- 4 (SEM) mg/dl, the result of decreased hepatic production of glucose (3.3 +/- 0.3 mg kg-1 min-1) insufficient to match glucose utilization (3.6 +/- 0.4 mg kg-1 min-1). The diminution of plasma glucose and of glucose production was similar whether ACTH deficiency was present (3.2 +/- mg kg-1 min-1) or not (3.5 +/- 0.6 mg kg-1 min-1). These results indicate that the lack of GH was the primary cause of hypoglycemia. Fasting plasma alanine (212 +/- 41 mumol/liter) and lactate (1222 +/- 136 mumol/liter), the main gluconeogenic substrates, were normal and did not correlate with the decrease of hepatic glucose release. Both plasma FFA (552 +/- 35 microM) and beta-hydroxybutyrate (654 +/- 158 microM) were in the low normal range, and neither correlated with the rate of glucose utilization. hGH replacement therapy resulted in a normalization of fasting plasma glucose concentration (78.5 +/- 6 mg/dl, P less than 0.005) and hepatic glucose production (6.1 +/- 1.2 mg kg-1 min-1). No significant changes occurred in the plasma concentrations of gluconeogenic or lipid substrates. These results, together with the known stimulatory effects of GH on carbohydrate-induced insulin secretion and storage of hepatic glycogen, suggest that the changes in glucose production in untreated and GH treated patients reflect the degree of hepatic glycogen replenishment.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3902870     DOI: 10.1210/jcem-61-6-1152

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  10 in total

1.  Distinct growth hormone receptor signaling modes regulate skeletal muscle development and insulin sensitivity in mice.

Authors:  Mahendra D Mavalli; Douglas J DiGirolamo; Yong Fan; Ryan C Riddle; Kenneth S Campbell; Thomas van Groen; Stuart J Frank; Mark A Sperling; Karyn A Esser; Marcas M Bamman; Thomas L Clemens
Journal:  J Clin Invest       Date:  2010-11       Impact factor: 14.808

2.  Loss of growth hormone-mediated signal transducer and activator of transcription 5 (STAT5) signaling in mice results in insulin sensitivity with obesity.

Authors:  Yash Chhabra; Caroline N Nelson; Monika Plescher; Johanna L Barclay; Aaron G Smith; Sof Andrikopoulos; Salvatore Mangiafico; David J Waxman; Andrew J Brooks; Michael J Waters
Journal:  FASEB J       Date:  2019-02-19       Impact factor: 5.191

3.  Effects of growth hormone and thyroxine replacement therapy on insulin signaling in Ames dwarf mice.

Authors:  Audreen Louis; Andrzej Bartke; Michal M Masternak
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2010-03-03       Impact factor: 6.053

4.  Sex differences in the prevalence of metabolic syndrome and its components in hypopituitary patients: comparison with an age- and sex-matched nationwide control group.

Authors:  Ah Reum Khang; Eu Jeong Ku; Ye An Kim; Eun Roh; Jae Hyun Bae; Tae Jung Oh; Sang Wan Kim; Chan Soo Shin; Seong Yeon Kim; Jung Hee Kim
Journal:  Pituitary       Date:  2016-12       Impact factor: 4.107

5.  Central ghrelin regulates peripheral lipid metabolism in a growth hormone-independent fashion.

Authors:  Susana Sangiao-Alvarellos; María J Vázquez; Luis Varela; Rubén Nogueiras; Asish K Saha; Fernando Cordido; Miguel López; Carlos Diéguez
Journal:  Endocrinology       Date:  2009-07-16       Impact factor: 4.736

6.  Inhibition of growth hormone action improves insulin sensitivity in liver IGF-1-deficient mice.

Authors:  Shoshana Yakar; Jennifer Setser; Hong Zhao; Bethel Stannard; Martin Haluzik; Vaida Glatt; Mary L Bouxsein; John J Kopchick; Derek LeRoith
Journal:  J Clin Invest       Date:  2004-01       Impact factor: 14.808

7.  Fasting enhances growth hormone secretion and amplifies the complex rhythms of growth hormone secretion in man.

Authors:  K Y Ho; J D Veldhuis; M L Johnson; R Furlanetto; W S Evans; K G Alberti; M O Thorner
Journal:  J Clin Invest       Date:  1988-04       Impact factor: 14.808

8.  Dilated cardiomyopathy in a cat with congenital hyposomatotropism.

Authors:  Bérénice Lutz; Adeline Betting; Alan Kovacevic; Alexane Durand; Corinne Gurtner; Taina S Kaiponen; Hans Kooistra; Miguel Campos; Yi Cui
Journal:  JFMS Open Rep       Date:  2022-03-30

9.  The role of PTEN in chronic growth hormone-induced hepatic insulin resistance.

Authors:  Yuan Gao; Peizhu Su; Chuqiong Wang; Kongqin Zhu; Xiaolan Chen; Side Liu; Jiman He
Journal:  PLoS One       Date:  2013-06-28       Impact factor: 3.240

10.  Juvenile hyposomatotropism in a Somali cat presenting with seizures due to intermittent hypoglycaemia.

Authors:  Maya Laura König; Diana Henke; Katja Adamik; Cristina Pérez Vera
Journal:  JFMS Open Rep       Date:  2018-03-09
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.